Though first and second generation of EGFR TKIs (gefitinib, erlotinib, and afatinib) show favorable clinical outcome (7), up to 70% of patients eventually develop TKI resistance and tumor relapses upon 9 to 15 months of TKI treatment (8). This evidence concerns the gene EGFR and neoplasm.